Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 4/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.37 |
| ▸ | CTSG | P08311 | 1/20 | 0.37 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.37 |
| ▸ | CMA1 | P23946 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 5/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | SMYD2 | Q9NRG4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1127293 | 0.89 | MAPT (0.40) | CYP2C9PPARAPRSS1CTSGCTRB1 | |
| SCHEMBL23295636 | 0.89 | PRSS1 (0.35) | CYP2C9PPARAPRSS1CTSGCTRB1 | |
| SCHEMBL1503891 | 0.87 | KCNN4 (0.41) | CYP2C9PRSS1CTSGCTRB1CMA1 | |
| SCHEMBL1691100 | 0.86 | CYP3A4 (0.35) | PPARAPRSS1CTSGCTRB1CMA1 | |
| SCHEMBL15007835 | 0.82 | MCL1 (0.33) | PRSS1CTSGCTRB1CMA1CYP3A4 | |
| SCHEMBL31443332 | 0.82 | SMYD2 (0.32) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL8168666 | 0.82 | SMYD2 (0.36) | CYP3A4HTTSMN1; SMN2SMYD2 | |
| SCHEMBL15159618 | 0.81 | PRSS1 (0.33) | PPARAPRSS1CTSGCTRB1CMA1 | |
| SCHEMBL31595483 | 0.81 | PPARA (0.55) | CYP2C9PPARACYP1A2SMN1; SMN2LTB4R | |
| SCHEMBL789538 | 0.81 | ALOX15 (0.41) | CYP3A4HTTSMN1; SMN2SMYD2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4649081-A1 | SULFONYLVINYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2025-11-19 | — | — | EP | disclosed |
| WO-2025072462-A1 | SULFONAMIDE DERIVATIVES AS CYCLIN-DEPENDENT KINASE 2 INHIBITORS | NIKANG THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20250051350-A1 | Dihydroartemisinin derivatives and the treatment of fibrotic diseases | GreenStone Biosciences, Inc. (US) | 2025-02-13 | — | — | US | disclosed |
| WO-2024149819-A1 | SULFONYLVINYL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-07-18 | — | — | WO | disclosed |
| EP-4392424-A1 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-07-03 | — | — | EP | disclosed |
| CN-117693509-A | Macrocyclic compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2024-03-12 | — | — | CN | disclosed |
| WO-2023159155-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) AND USES THEREOF | PIVALENT THERAPEUTICS, INC. (US) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023025832-A1 | MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2023-03-02 | — | — | WO | disclosed |
| US-10017508-B2 | Nitrogenated heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-10 | — | — | US | disclosed |
| EP-2848618-B1 | NITROGENATED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-03-14 | — | — | EP | disclosed |
| US-7342014-B2 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20080015215-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-01-17 | — | — | US | disclosed |
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-11-09 | — | — | US | disclosed |
| US-6982257-B1 | Vitamin D3 derivative and its production method | TEIJIN LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20050245565-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050119486-A1 | Diamine derivatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2005-06-02 | — | — | US | disclosed |
| US-20050020645-A1 | Diamine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-01-27 | — | — | US | disclosed |
| EP-1415992-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-05-06 | — | — | EP | disclosed |
| EP-1405852-A1 | DIAMINE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060252837-A1 | Cyclic diamine derivatives useful as agents for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism; inhibit activated blood coagulation factor X | F2, C1S, C9 | CYP2C9 1853/4885PPARA 3513/4885PRSS1 166/4885 |
| US-20050020645-A1 | Diamine derivatives | C9, C1S, C1R | CYP2C9 1538/4885PPARA 4308/4885PRSS1 412/4885 |
| US-20080015215-A1 | DIAMINE DERIVATIVES | C9, C1S, C1R | CYP2C9 1538/4885PPARA 4308/4885PRSS1 412/4885 |
| US-20050245565-A1 | Diamine derivatives | C9, C1S, C1R | CYP2C9 1538/4885PPARA 4308/4885PRSS1 412/4885 |
| US-20050119486-A1 | Diamine derivatives | C9, C1S, C1R | CYP2C9 1538/4885PPARA 4308/4885PRSS1 412/4885 |
| US-10017508-B2 | Nitrogenated heterocyclic compound | PDE2A, PDE5A, PDE3A | CYP2C9 1356/4885PPARA 1415/4885PRSS1 1874/4885 |
| US-20250051350-A1 | Dihydroartemisinin derivatives and the treatment of fibrotic diseases | PTGES3, PTGIS, COL14A1 | CYP2C9 2938/4885PPARA 1314/4885PRSS1 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.